10/2023

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

10/2023

Oct 23, 2023, 17:30 | Blog
Kelly Shanahan: Sheila Johnson is a clinical trial hero!
Kelly Shanahan, member of the Metastatic Breast Cancer Alliance, shared a post by MBC Alliance…
Oct 23, 2023, 17:28 | Blog
Jessica Clerc: Recognizing a great NGO often comes down to the quality of its board and team!
Jessica Clerc, Partnership Manager at UICC, shared on LinkedIn: “Recognizing a great NGO often comes…
Oct 23, 2023, 17:21 | Blog
Tara Frenkl: Navigating the complexities of life after a prostate cancer diagnosis goes beyond the physical
Tara Franklin, Head of Oncology Department at Bayer, shared on LinkedIn: “Navigating the complexities of…
Oct 23, 2023, 17:17 | Blog
Nigeria on the Path to Cervical Cancer Elimination by Zainab Shinkafi-Bagudu - Medicaid CF Programs
Medicaid CF Programs shared a post on X/Twitter: “HPV Vaccine: Nigeria on the Path to…
Oct 23, 2023, 17:15 | Insight
María Natalia Gandur Quiroga: Disappointing update from ESMO 23: Christina Gratzke reveals KEYNOTE-991 study results.
Quoting María Natalia Gandur Quiroga on X/Twitter: “Disappointing update from ESMO 23: Christina Gratzke reveals KEYNOTE-991…
Oct 23, 2023, 15:51 | Blog
Princess Dina Mired: As a mother of a cancer survivor, my heart goes out to all the innocent children in Gazza who now have to wait whilst cancer is ravaging their tiny bodies since there is no more chemotherapy
Oct 23, 2023, 15:40 | Blog
Erika Hamilton: Not all AEs are equal...
Erika Hamilton shared a post by Hope Rugo on X/Twitter: “Not all AEs are equal…
Oct 23, 2023, 15:35 | Blog
Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT
Julien Mazières, Thoracic Oncology Specialist at Toulouse University Hospital, France, shared insights from the ALINA…
Oct 23, 2023, 15:26 | Insight
Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)
Tom Powles, Director of Barts Cancer Centre, shared on Twitter: "Enfortumab vedotin and Pembrolizumab improving…
Oct 23, 2023, 15:24 | Insight
Why radiotherapy with concomitant chemotherapy is an excellent option for bladder preservation in bladder cancer patients
Pierre Blanchard, Full Professor of Radiation Oncology at Gustave Roussy Cancer Center, posted on his…
All: 805 Posts: 191 - 200